Radiation Therapy + Temozolomide

DRUG2 trials

Sponsors

Bradmer Pharmaceuticals Inc., Massachusetts General Hospital

Conditions

Glioblastoma (GBM)Glioblastoma MultiformeMGMT-Methylated GlioblastomaNewly Diagnosed Glioblastoma Multiforme

Phase 2

G-CSF After Chemo-radiation in Patients With Glioblastoma

RecruitingNCT06649851

Massachusetts General HospitalGlioblastoma (GBM), MGMT-Methylated Glioblastoma, Newly Diagnosed Glioblastoma Multiforme

Start: 2025-04-02End: 2030-01-31Target: 60Updated: 2025-09-25

Phase 3

Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy

TerminatedNCT00615186

Bradmer Pharmaceuticals Inc.Glioblastoma Multiforme

Start: 2008-06-30End: 2013-12-31Updated: 2011-02-10